ACOR News and Press, Acorda Therapeutics Inc. From 08/02/19

Gainers:  Aphria (NYSE: APHA ) +36% . Natural Grocers by Vitamin Cottage (NYSE: NGVC ) +33% . BlackLine (NASDAQ: BL ) +29% . Regional Health Properties (NYSEMKT: RHE ) +22% . Griffon Corporation (NYSE: GFF ) +20% . PC Connection (NASDAQ: CNXN ) +19% . Pinterest (NYSE: PINS ) +1...

Acorda Therapeutics ( ACOR -43.7% ) slumps on more than double normal volume after reporting Q2 results after the close yesterday. More news on: Acorda Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...

Acorda Therapeutics, Inc. (ACOR) Q2 2019 Earnings Conference Call August 01, 2019, 04:30 PM ET Company Participants Felicia Vonella - Executive Director, IR Ron Cohen - CEO Lauren Sabella - CCO David Lawrence - CTO, Chief of Business Operations & Principal Accounting Office...

Acorda Therapeutics (NASDAQ: ACOR ): Q2 Non-GAAP EPS of -$0.55 beats by $0.51 ; GAAP EPS of -$0.58 beats by $0.68 . More news on: Acorda Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

INBRIJA™ (levodopa inhalation powder) 2Q 2019 net sales of $3.0 million CHMP issues positive opinion on INBRIJA AMPYRA ® (dalfampridine) 2Q 2019 net sales of $44.0 million Acorda Therapeutics, Inc. (NASDAQ: ACOR ) provided a financial and pipeline update for the...

ACA , ACOR , AIV , ALEX , ANET , APHA , BFAM , BGS , BIO , BL , BLDR , BMRN , BRKR , BRKS , BZH , CATM , CBLK , CC , CENT , CENX , CERS , CORT , CRC , CWK , CWST , DLB , DVA , EBS , ECOL , ED , ENSG , EOG , ERII , ETSY , FBHS , FLDM , FLR , FND , FRT , ...

Acorda Therapeutics, Inc. (NASDAQ: ACOR) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending INBRIJA’s approval by the European Commission (EC). The recommended indication is: Inb...

Acorda Therapeutics ( ACOR ) is in an unfavorable position with its (now former) main product Ampyra now a generic, the main existing asset Inbrija just entering the market and the company expected to burn a significant amount of cash in the following quarters. To further complicate matters ...

Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast to report its second quarter 2019 update and financial results on Thursday, August 1 at 4:30 p.m. ET. To participate in the conference call, please dial (866) 393-4306 (domestic) or (734) 385-2616 (internatio...

Acorda Therapeutics ( ACOR ) has had a difficult year with the genericization of their AMPYRA asset coming from a court decision in September 2018. The company has lost over half of its equity value YTD and investors have been continually selling shares even amidst a strong bull market. Howe...